Array BioPharma (ARRY) to Release Earnings on Tuesday
Array BioPharma (NASDAQ:ARRY) will be posting its Q314 quarterly earnings results on Tuesday, April 29th. Analysts expect Array BioPharma to post earnings of ($0.21) per share and revenue of $9.40 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.
Array BioPharma (NASDAQ:ARRY) last posted its quarterly earnings results on Tuesday, February 4th. The company reported ($0.13) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.16) by $0.03. The company had revenue of $14.10 million for the quarter, compared to the consensus estimate of $13.49 million. During the same quarter last year, the company posted ($0.10) earnings per share. Array BioPharma’s revenue was down 23.4% compared to the same quarter last year. On average, analysts expect Array BioPharma to post $-0.69 EPS for the current fiscal year and $-0.65 EPS for the next fiscal year.
Shares of Array BioPharma (NASDAQ:ARRY) opened at 3.86 on Monday. Array BioPharma has a 52 week low of $3.39 and a 52 week high of $7.10. The stock’s 50-day moving average is $4.53 and its 200-day moving average is $5.04. The company’s market cap is $484.3 million.
On a related note, analysts at Zacks downgraded shares of Array BioPharma from an “outperform” rating to a “neutral” rating in a research note on Wednesday, February 19th. They now have a $5.40 price target on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Array BioPharma has a consensus rating of “Buy” and an average target price of $6.35.
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.